Nilogen Oncosystems’ Post

Biosimilars Battle Cancer: New Wins You Need to Know! Docs just dropped the mic on biosimilars in oncology! ️We're talking new research, doc success stories, and how these treatments are changing the game for patients. ⚕️ Want to know more? We've got the scoop in this month's Biosimilars Oncology Roundup! https://lnkd.in/ePPx3MDr

Oncology clinical trials are on the rise! Two trends are emerging in cancer treatment: the development of cancer-targeting drugs and the influx of biomarkers. Each oncology trial presents unique challenges, from multifaceted study protocols to diverse sample types. In this article, we will dive into the complexities of early oncology clinical trials, with a specific focus on sample management. Read article 👉 https://lnkd.in/eQMrJ65b #healthscience #cancerresearch #oncology

The damage to the heart is one of the most serious side effects of cancer treatment, as the heart has no ability to repair itself. Race CEO Dr Daniel Tillett joins Stockhead for their What the Facts?! (WTF) video interview series to discuss what makes cancer treatment uniquely difficult, and why patient heart health is important in this process.   Watch the full video in the link below.   #chemotherapy #cardioprotection

Support your team with the insight they need to make decisions. Stay competitive with Oncology Resource Group's Pipeline Strategies Reports. Drug development for ovarian cancer has been shifting from IO and PARP inhibitors to ADCs. ONCrg stays on top of the news, big and small, to save your team time and to ensure competitor activities are reliably interpreted. Contact Brittany Daggett or Erica Wescott, MSc. to see more of our ONCrg Pipeline Strategies: Ovarian Cancer report, or for other solid tumors, hematologic malignancies, and MOAs. Unrivaled Insights, Unmatched Expertise #Oncology #CompetitiveStrategy #OvarianCancerAwareness #competitivelandscape

The countdown for the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting is on and we're excited to meet you in Chicago. Schedule a meeting with our team to discover how our AI-driven spatial biomarkers are advancing next-gen cancer treatments, like bi-specifics, ADCs, and immunotherapies.—because next-gen oncology treatments need next-gen biomarkers! https://bit.ly/3UFaMwY #ASCO24, #biomarkers #spatialbiomarkers #CDx #SpatialBiology #PrecisionOncology #PrecisionMedicine #DigitalPathology #ClinicalTrials #Oncology

Watch our webinar with Race Oncology featuring CEO Daniel Tillett. The webinar will commence with a presentation, followed by a live Q&A with the audience, providing you the opportunity to ask Daniel any questions about RAC that you may have. Key topics: - Background to Race Oncology and their developments - What bisantrene could mean for cancer patients around the world - Why cardioprotection is so important in regards to cancer treatment - What stage they are at with the clinical development process - The company's upcoming milestones - Why investors should be interested in Race Oncology Register here:

iTeos Therapeutics and GSK reach a pivotal milestone! 👨🔬 The duo has begun their Phase III TIGIT lung cancer trial, marking a significant step forward in #CancerResearch. This trial explores the potential of combining belrestotug with Jemperli for non-small cell lung cancer treatment. 🌍 As the trial commences, we're reminded of the global impact such breakthroughs have. With rising cases worldwide, advancements like these are more crucial than ever. For anyone interested in exploring new opportunities in this dynamic sector, reach out or check out elixir-associates.com. #Oncology #ClinicalTrials #Innovation

$ELEV CEO Joseph Ferra spoke with Karen Jagoda of the Empowered Patient Podcast to discuss the use of Antibody Drug Conjugates (ADCs) targeting Claudin 18.2 to treat gastric cancer, ongoing clinical trials and the future of ADCs in oncology. Learn how this approach is addressing the high unmet needs in gastric cancer treatment and offering hope for better patient outcomes. Listen to the full episode here: https://lnkd.in/ejmM4eNE #GastricCancer #Oncology #Podcast

🌍 With global cancer cases projected to surge by 77% by 2050, staying at the forefront of oncology research and treatment is more important than ever. This month's edition of Veristat's Voyager newsletter dives deep into how our innovative approaches are accelerating positive outcomes in cancer trials. Find out how our efforts are decreasing the workload for sponsors and, more importantly, increasing hope for patients > https://lnkd.in/esPvwk6U #Veristat #Oncology #Cancer

Looking to hear expert opinions on the latest therapeutic developments in oncology? Watch our on-demand Roundtable discussion: Therapeutic Developments and Innovative Strategies in Oncology. Here, three KOLs in pharma, academia and biotech explore a number of cancer-related topics including: - The complexity of cancer: the interplay between a tumor and its microenvironment - Current therapeutic approaches in oncology - Their successes and failures - How to develop the best near-patient models in immuno-oncology and the most promising novel therapeutic approaches towards cancer Don't miss this opportunity to learn from the best in the field! https://lnkd.in/eKsPH6MC #oncology #cancerresearch #immunooncology #roundtablediscussion